Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Bryostatin 1 in Treating Patients With Ovarian Epithelial Cancer

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: November 1, 1999
Last updated: June 25, 2013
Last verified: November 1999

November 1, 1999
June 25, 2013
July 1999
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00004008 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Bryostatin 1 in Treating Patients With Ovarian Epithelial Cancer
A Phase II Trial of Bryostatin 1 in Ovarian Cancer Administered by Weekly 24 Hour Intravenous Infusion

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients who have ovarian epithelial cancer that has not responded to previous chemotherapy.


  • Evaluate the antitumor activity and toxicity of bryostatin 1 in patients with platinum resistant ovarian epithelial cancer.
  • Determine the response rate in patients treated with this regimen.

OUTLINE: This is a multicenter study.

Patients receive bryostatin 1 IV over 24 hours. Treatment repeats weekly for 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable or regressive disease may receive additional treatment.

Patients are followed for at least 4 weeks after treatment, then every 3 months.

PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.

Phase 2
Primary Purpose: Treatment
Ovarian Cancer
Drug: bryostatin 1
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
May 2003
Not Provided


  • Histologically proven ovarian epithelial cancer

    • Progressive disease during or after completion of at least one platinum based chemotherapy regimen
  • Bidimensionally measurable disease

    • At least 2 cm by x-ray, CT scan, or ultrasound
  • No active, symptomatic brain metastases (e.g., cerebral edema and/or progressive tumor growth)



  • 18 and over

Performance status:

  • WHO 0-2

Life expectancy:

  • At least 12 weeks


  • Hemoglobin at least 10 g/dL
  • WBC at least 4,000/mm3
  • Platelet count at least 100,000/mm3


  • Bilirubin no greater than 1.7 mg/dL
  • AST/ALT no greater than 2.5 times upper limit of normal (ULN) (no greater than 5 times ULN if liver metastases present)


  • Creatinine no greater than 1.4 mg/dL


  • No active, uncontrolled infection
  • No nonmalignant systemic disease which would increase risk to patient
  • No other malignancies within the past 5 years except curatively treated basal or squamous cell skin cancer or carcinoma in situ of the cervix
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 2 months after study


Biologic therapy:

  • At least 4 weeks since prior immunotherapy and recovered


  • See Disease Characteristics
  • At least 4 weeks since prior chemotherapy (6 weeks since nitrosoureas or mitomycin) and recovered
  • No more than 2 prior multidrug chemotherapy regimens
  • No more than 1 prior single agent chemotherapy regimen

Endocrine therapy:

  • At least 4 weeks since prior endocrine therapy and recovered
  • No concurrent steroids
  • Concurrent hormone replacement therapy allowed


  • At least 4 weeks since prior radiotherapy (excluding palliative therapy) and recovered
  • No concurrent radiotherapy


  • At least 4 weeks since prior major thoracic or abdominal surgery


  • No other concurrent anticancer therapy or investigational drugs
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United Kingdom
CRC-PHASE-II-PH2/039, CDR0000067219, NCI-T99-0027
Not Provided
Not Provided
Not Provided
Not Provided
University of Glasgow
Not Provided
Study Chair: Gordon Jayson, MD The Christie NHS Foundation Trust
National Cancer Institute (NCI)
November 1999

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP